On a global level, the companies represented here currently register industry sponsored clinical trials with innovative medicines in patients on a public registry (e.g. clinicaltrials.gov), and are already disclosing summary results of these clinical trials through publicly accessible websites. The outcome of the planned consensus study will provide the basis for a model to further enhance access to clinical trial data, and in doing so, contribute to improved scientific exchange, increased knowledge generation, and greater public understanding of the benefits and risks of medicines.For media inquiries, please contact any of the companies listed.
Industry Group Supports Uniform Approach To Transparency Of Clinical Trial Data
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts